MAPK3 and neoplasm: Thus, withdrawing drug to activate ERK1/2 or increasing the selumetinib concentration to more strongly inhibit ERK1/2 impaired tumour growth, consistent with a narrow window of ERK1/2 activity maintaining C6244-R tumour growth in vivo (Fig. 5o).